MDCX · Categories · Conferences
MDCX - Conference and earnings call announcements
Medicus Pharma Ltd. (MDCX) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for MDCX
- Medicus Pharma To Participate in the 38th Annual Roth ConferencePHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will be participating in the 38th Annual Roth Conference, being held March 22-24, 2026, in Dana Point, California. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will participate in a Fireside Chat hosted by Roth Capital Partners Managing Director and Senior Research Analyst Jonathan Aschoff. Dr. Bokhari will review the clinical development programs of the company, especially Skinject's potential effica
- Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness AcceleratesPHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion programs. Biotech Showcase Presentation Details Presentation Date:Tuesday, January 13, 2026Time:10:00 a.
- Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the SkinPHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner's national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The submission includes a complete Statement of Interest outlining SkinJect's alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs.